Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT05549609

A Study of XSTEM-VLU in Patients With Difficult-to-heal Venous Leg Ulcers

Led by Xintela AB · Updated on 2025-05-04

6

Participants Needed

4

Research Sites

153 weeks

Total Duration

On this page

Sponsors

X

Xintela AB

Lead Sponsor

V

Vinnova

Collaborating Sponsor

AI-Summary

What this Trial Is About

The aim of the study is to assess safety, tolerability and preliminary efficacy of XSTEM-VLU when administered as a single topical dose to patients with difficult-to-heal venous leg ulcers. The study is randomised and the patients will receive either XSTEM-VLU or vehicle as add on to standard wound care. The patients will be followed weekly for 10 weeks after treatment. At 4 months after treatment, the patients will return to the clinic for an end-of-study visit.

CONDITIONS

Official Title

A Study of XSTEM-VLU in Patients With Difficult-to-heal Venous Leg Ulcers

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

Major

  • Written informed consent for participation in the study
  • Male or female patient aged ≥18 years
  • BMI ≥18.5 and ≥40.0 kg/m2
  • Lower leg wound due to venous insufficiency
  • Target wound has failed to heal despite standard wound care for a minimum of 6 weeks
  • A surface area of the target wound of ≥2 and ≤40 cm2

Major

Not Eligible

You will not qualify if you...

  • Signs or symptoms of clinically significant ongoing infection i the target wound requiring anti-microbial treatment
  • History of autoimmune disease, such as but not limited to systemic lupus erythematosus, Addison's disease, Crohn's disease and type I diabetes mellitus
  • B-HbA1C value ≥52 mmol/mol
  • Plaque psoriasis or any other skin disease that could interfere with the outcome of the study
  • Arterial insufficiency
  • History of any malignancy within the past 5 years
  • Target wound diagnosed as a malignant wound, neuropathic wound, pressure wound or osteomyelitis
  • Patients who are immunocompromised due to disease or for other reasons such as the use of systemic immunosuppressants

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Clinical Trial Center (CTC)

Gothenburg, Sweden, SE-413 46

Actively Recruiting

2

Burn Centre, Linköping University Hospital

Linköping, Sweden, SE-581 85

Withdrawn

3

Clinical Research Unit

Lund, Sweden, SE-221 85

Withdrawn

4

Clinical Trial Consultants (CTC) Karolinska

Stockholm, Sweden, SE-171 64

Actively Recruiting

Loading map...

Research Team

C

Central contact

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here